◎ Sugi Atlas

Atlas / Disease / Bacterial infectious disease with sepsis

Bacterial infectious disease with sepsis

disease
On this page

Also known as bacteremiaBacteremiassymptomatic bacteremia

Summary

Bacterial infectious disease with sepsis (MONDO:0005229) is a disease (an umbrella term covering 5 Mondo subtypes) with 6 cohort genes (13 GWAS associations across 10 studies) and 178 clinical trials. Top therapeutic interventions include daptomycin, vancomycin, and chlorhexidine.

At a glance

  • Umbrella term: 5 Mondo subtypes
  • Cohort genes: 6
  • GWAS associations: 13
  • Clinical trials: 178

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namebacterial infectious disease with sepsis
Mondo IDMONDO:0005229
EFOEFO:0003033
MeSHD016470
DOIDDOID:0040085
SNOMED CT5758002
UMLSC0004610
MedGen482
Is cancer (heuristic)no

Also known as: bacteremia · Bacteremias · symptomatic bacteremia

Data availability: 13 GWAS associations (10 studies).

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial infectious disease with sepsis

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (5): gas gangrene, Pasteurella hemorrhagic septicemia, Lemierre syndrome, meningococcemia, neonatal sepsis

Genetics & variants

GWAS landscape

13 GWAS associations across 10 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs76330541e-07PTPRG?1.36
rs5607743442e-07ADAM8?
rs46947447e-07UGT2B24P - UGT2B4?1.59
rs108402702e-06RPL23AP65 - RPL21P97?1.25
rs8001602e-06CD81-AS1?1.24
rs98698264e-06DOCK3?1.27
rs15008014e-06PALLD?1.64
rs77250384e-06SH3RF2?1.3
rs66690085e-06MAGI3?1.32
rs119599755e-06LINC02112?1.27
rs96520208e-06LINC02555?1.27
rs72404628e-06LINC01899 - CBLN2?1.19
rs67163689e-06AHCYP4 - SNORA72?1.26

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90477027Verma A20248,436437,514Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651997Liu TY20255,892213,110Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90477026Verma A20242,384117,942Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480968Verma A20242,384117,942Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST008910Trochet H20191,78723,008Bayesian meta-analysis across genome-wide association studies of diverse phenotypes.
GCST90041711Jiang L20211,634454,714A generalized linear mixed model association tool for biobank-scale data.
GCST003650Rautanen A20161,5362,677Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children.
GCST90477025Verma A20241,10858,086Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90041709Jiang L2021383455,965A generalized linear mixed model association tool for biobank-scale data.
GCST90041710Jiang L2021168456,180A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic13

MAF distribution

BucketVariants
common (>=0.05)12
low_freq (0.01-0.05)0
rare (<0.01)0
unknown1

Functional consequences

ConsequenceCount
intron_variant9
intergenic_variant3
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs7633054362153280C>A,G,T0.05intron_variantPTPRG1e-07Tier 4: intronic/intergenic
rs56077434410133271383T>Cintron_variantADAM82e-07Tier 4: intronic/intergenic
rs4694744469460938T>C0.05intergenic_variantUGT2B24P - UGT2B47e-07Tier 4: intronic/intergenic
rs10840270119608006C>G,T0.05intron_variantRPL23AP65 - RPL21P972e-06Tier 4: intronic/intergenic
rs800160112358904T>C0.05intron_variantCD81-AS12e-06Tier 4: intronic/intergenic
rs9869826350961385T>C0.05intron_variantDOCK34e-06Tier 4: intronic/intergenic
rs15008014168747226A>C,G,T0.05intron_variantPALLD4e-06Tier 4: intronic/intergenic
rs77250385146008617C>T0.05intron_variantSH3RF24e-06Tier 4: intronic/intergenic
rs66690081113623939A>G0.05intron_variantMAGI35e-06Tier 4: intronic/intergenic
rs1195997559902717G>A0.05non_coding_transcript_exon_variantLINC021125e-06Tier 4: intronic/intergenic
rs96520201240153577G>A,C0.05intron_variantLINC025558e-06Tier 4: intronic/intergenic
rs72404621871995346C>T0.05intergenic_variantLINC01899 - CBLN28e-06Tier 4: intronic/intergenic
rs67163682139166548G>A0.05intergenic_variantAHCYP4 - SNORA729e-06Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PALLDOrphanet:1333Familial pancreatic carcinoma
DOCK3Orphanet:528084Non-specific syndromic intellectual disability

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only6

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
UGT2B4HGNC:12553ENSG00000156096P06133UDP-glucuronosyltransferase 2B4gwas
PALLDHGNC:17068ENSG00000129116Q8WX93Palladingwas
SH3RF2HGNC:26299ENSG00000156463Q8TEC5E3 ubiquitin-protein ligase SH3RF2gwas
MAGI3HGNC:29647ENSG00000081026Q5TCQ9Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3gwas
DOCK3HGNC:2989ENSG00000088538Q8IZD9Dedicator of cytokinesis protein 3gwas
PTPRGHGNC:9671ENSG00000144724P23470Receptor-type tyrosine-protein phosphatase gammagwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
UGT2B4UDP-glucuronosyltransferase 2B4UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
PALLDPalladinCytoskeletal protein required for organization of normal actin cytoskeleton.
SH3RF2E3 ubiquitin-protein ligase SH3RF2Has E3 ubiquitin-protein ligase activity.
MAGI3Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3Acts as a scaffolding protein at cell-cell junctions, thereby regulating various cellular and signaling processes.
DOCK3Dedicator of cytokinesis protein 3Potential guanine nucleotide exchange factor (GEF).
PTPRGReceptor-type tyrosine-protein phosphatase gammaPossesses tyrosine phosphatase activity.

Protein-family classification

Druggable: 4 · Difficult: 2 · Unknown: 0 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Phosphatase114.0×0.396
Antibody/Immunoglobulin14.9×0.396
Kinase14.6×0.396
Scaffold/PPI12.9×0.451
Enzyme (other)12.0×0.488
Transcription factor11.4×0.539

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
UGT2B4Enzyme (other)yes2.4.1.17UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
PALLDAntibody/ImmunoglobulinyesIg_sub2, Ig_sub, Ig-like_dom
SH3RF2Transcription factornoSH3_domain, Znf_RING, Znf_RING/FYVE/PHD
MAGI3KinaseyesWW_dom, PDZ, Guanylate_kin-like_dom
DOCK3Scaffold/PPInoSH3_domain, ARM-type_fold, DOCK
PTPRGPhosphataseyes3.1.3.48PTP_cat, Tyr_Pase_dom, CA_dom

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)6
unknown0

Top tissues across cohort

TissueCohort genes
heart right ventricle2
lower lobe of lung2
liver1
primordial germ cell in gonad1
right lobe of liver1
blood vessel layer1
saphenous vein1
apex of heart1
left ventricle myocardium1
ileal mucosa1
nasal cavity epithelium1
Brodmann (1909) area 101
frontal pole1
paraflocculus1
calcaneal tendon1
caput epididymis1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
UGT2B496tissue_specificmarkerliver, right lobe of liver, primordial germ cell in gonad
PALLD302ubiquitousmarkersaphenous vein, heart right ventricle, blood vessel layer
SH3RF2210ubiquitousmarkerleft ventricle myocardium, apex of heart, heart right ventricle
MAGI3250ubiquitousmarkerlower lobe of lung, nasal cavity epithelium, ileal mucosa
DOCK3203broadmarkerfrontal pole, Brodmann (1909) area 10, paraflocculus
PTPRG261ubiquitousmarkercalcaneal tendon, lower lobe of lung, caput epididymis

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
MAGI33,725
PTPRG2,642
PALLD2,362
DOCK31,481
UGT2B4942
SH3RF2661

Intra-cohort edges

ABSources
MAGI3PTPRGintact

Structural data

PDB: 3 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
PTPRGP2347020
PALLDQ8WX932
MAGI3Q5TCQ91

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
UGT2B4P0613394.03
DOCK3Q8IZD975.52
SH3RF2Q8TEC557.92

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 7. Enrichment computed across 6 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
NTRK2 activates RAC11951.7×0.007DOCK3
Glucuronidation1380.7×0.009UGT2B4
Aspirin ADME1158.6×0.015UGT2B4
RHOG GTPase cycle174.2×0.022DOCK3
RAC2 GTPase cycle163.4×0.022DOCK3
Factors involved in megakaryocyte development and platelet production133.2×0.032DOCK3
RAC1 GTPase cycle130.5×0.032DOCK3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
keratinocyte development1255.3×0.036PALLD
negative regulation of epithelial cell migration1175.5×0.036PTPRG
neurotrophin TRK receptor signaling pathway1175.5×0.036DOCK3
dendrite self-avoidance1175.5×0.036PALLD
epithelial cell morphogenesis1156.0×0.036PALLD
estrogen metabolic process1104.0×0.043UGT2B4
negative regulation of JNK cascade193.6×0.043SH3RF2
negative regulation of protein ubiquitination147.6×0.069SH3RF2
negative regulation of neuron projection development139.6×0.069PTPRG
protein autoubiquitination139.0×0.069SH3RF2
positive regulation of proteasomal ubiquitin-dependent protein catabolic process135.1×0.069SH3RF2
small GTPase-mediated signal transduction130.5×0.069DOCK3
cell surface receptor protein tyrosine kinase signaling pathway129.0×0.069PTPRG
positive regulation of JNK cascade127.3×0.069SH3RF2
xenobiotic metabolic process124.9×0.069UGT2B4
regulation of small GTPase mediated signal transduction124.0×0.069DOCK3
homophilic cell-cell adhesion123.4×0.069PALLD
cytoskeleton organization122.1×0.069PALLD
neuron projection development120.4×0.069PTPRG
signal transduction25.3×0.069MAGI3, PTPRG
axon guidance115.1×0.086PALLD
actin cytoskeleton organization113.2×0.094PALLD
positive regulation of cell migration110.3×0.109SH3RF2
cell migration110.2×0.109PALLD
protein ubiquitination16.9×0.153SH3RF2
intracellular signal transduction16.3×0.159MAGI3
negative regulation of apoptotic process15.8×0.167SH3RF2
apoptotic process14.8×0.192MAGI3

Therapeutics

Drugs indicated for this disease

4 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
DaptomycinApproved (phase 4)
LinezolidApproved (phase 4)
MeropenemApproved (phase 4)
Penicillin VApproved (phase 4)
AlcoholPhase 3 (in late-stage trials)
CefazolinPhase 3 (in late-stage trials)
ChlorhexidinePhase 3 (in late-stage trials)
DicloxacillinPhase 3 (in late-stage trials)
OxacillinPhase 3 (in late-stage trials)
TelavancinPhase 3 (in late-stage trials)
TemocillinPhase 3 (in late-stage trials)
VancomycinPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetylcysteine, Amoxicillin, Colistin, Dalbavancin, Heparin, Nafcillin, Neomycin, Nystatin, Tigecycline.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 6

Druggability breadth: 3 of 6 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
UGT2B400
PALLD00
SH3RF200
MAGI300
DOCK300
PTPRG00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
UGT2B458ADMET:57, Binding:1
PTPRG22Binding:21, ADMET:1
MAGI34Binding:4

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
UGT2B42.4.1.17glucuronosyltransferase
PTPRG3.1.3.48protein-tyrosine-phosphatase

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug3PALLD, MAGI3, PTPRG
DDruggable family + AlphaFold only, no drug1UGT2B4
EDifficult family or no structure, no drug2SH3RF2, DOCK3

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
UGT2B458—
PALLD0—
SH3RF20—
MAGI34—
DOCK30—
PTPRG22—

Clinical trials & evidence

Clinical trials

Clinical trials: 178.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified121
PHASE425
PHASE313
PHASE210
PHASE2/PHASE34
PHASE1/PHASE22
PHASE12
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03671967PHASE4RECRUITINGPipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
NCT05770622PHASE4RECRUITINGImproving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)
NCT06422221PHASE4NOT_YET_RECRUITINGAn Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures
NCT07240077PHASE4NOT_YET_RECRUITINGBeta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia
NCT00164099PHASE4TERMINATEDThe Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study
NCT00406198PHASE4COMPLETEDImpact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis
NCT00417235PHASE4COMPLETEDDressing: Frequency of Change and Evaluation of an Antiseptic-Impregnated Catheter Dressing in ICU Patients
NCT00515151PHASE4COMPLETEDPrevention of Catheter-Associated Infection With the Skin Disinfectant Octenidine Dihydrochloride
NCT00571259PHASE4COMPLETEDProphylactic Antimicrobial Catheter Lock
NCT00609375PHASE4COMPLETEDEfficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
NCT01287832PHASE4TERMINATEDVancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
NCT01450358PHASE4COMPLETEDEvaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.
NCT01728376PHASE4COMPLETEDSafety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
NCT01734694PHASE4TERMINATEDSafety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
NCT01919593PHASE4COMPLETEDEfficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compare 10% Povidone Iodine in Blood Culture in Children
NCT02150031PHASE4COMPLETEDBacteraemia Secondary to Tooth Extraction: Chlorhexidine Prophylaxis Protocols
NCT02660346PHASE4COMPLETEDIL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
NCT02972983PHASE4COMPLETEDDaptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
NCT03108690PHASE4WITHDRAWNTherapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia
NCT04044703PHASE4COMPLETEDImproving Dosing of Vancomycin in Young Infants With Infections
NCT04673175PHASE4TERMINATEDCeftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
NCT04882085PHASE4COMPLETEDEfficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
NCT05355350PHASE4WITHDRAWNPipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
NCT05521880PHASE4TERMINATEDAnchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
NCT05799716PHASE4UNKNOWNTreating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
NCT05224401PHASE3RECRUITINGPivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs
NCT00027248PHASE3COMPLETEDSafety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
NCT00037050PHASE3COMPLETEDAntibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT00093067PHASE3COMPLETEDDaptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
NCT00108433PHASE3TERMINATEDLinezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
NCT00122642PHASE2/PHASE3COMPLETEDAlcohol Locks for the Prevention of Tunneled Catheter-related Infections
NCT00398411PHASE3COMPLETEDMoxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
NCT00518687PHASE2/PHASE3TERMINATEDEfficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
NCT00735813PHASE3COMPLETEDTaurolidine Lock Solution in the Prevention of Catheter Related Bacteremia
NCT01186172PHASE3UNKNOWNEthanol Lock for the Salvage of Infected Long-term Vascular Access
NCT01798537PHASE2/PHASE3UNKNOWNSimplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired Infections
NCT01820962PHASE3TERMINATEDConcentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients
NCT02134106PHASE2/PHASE3WITHDRAWNRandomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
NCT02168946PHASE3COMPLETEDEfficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
NCT02208063PHASE3TERMINATEDA Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DAPTOMYCIN49
VANCOMYCIN45
CHLORHEXIDINE43
CLINDAMYCIN43
DOXYCYCLINE ANHYDROUS43
MEROPENEM43
PENICILLIN G43
PIPERACILLIN43
AMOXICILLIN42
CEFTAROLINE FOSAMIL42
CITRIC ACID42
CLAVULANIC ACID42
DALBAVANCIN42
HEPARIN42
IMIPENEM ANHYDROUS42
LINEZOLID42
TAZOBACTAM42
TELAVANCIN42
CEFAZOLIN41
CEFEPIME41
CEFTAZIDIME41
CEFTOBIPROLE MEDOCARIL FREE ACID41
CEFTOBIPROLE MEDOCARIL SODIUM41
CEFTOLOZANE41
CILASTATIN41
COLISTIMETHATE SODIUM41
COLISTIN41
DICLOXACILLIN41
DORIPENEM41
DURLOBACTAM41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 69

This page pulls from 69 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentorphanetpatentpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot